» Articles » PMID: 30476873

Understanding Treatment Decisions from the Perspective of People with Relapsing Remitting Multiple Sclerosis: A Critical Interpretive Synthesis

Overview
Specialty Neurology
Date 2018 Nov 27
PMID 30476873
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system that mainly affects young adults. While there is no cure for MS, disease modifying treatments (DMTs) reduce the relapse rate and partial accrual of disability. More effective DMTs may have higher risks including life-threatening infections or secondary autoimmunity. The complexity and novelty of available treatments cause challenges for clinicians when prescribing treatments and for people with MS (PwMS) when deciding what trade-offs they are willing and ready to make.

Objective: To explore the experience of people with relapsing remitting MS (PwRRMS) and their perspectives in choosing treatments.

Methods: Critical interpretive synthesis was employed to review and synthesis the published literature. Eighty-three publications were selected in a multi-step systematic process.

Results: Findings are presented in four interrelated areas: the influence of the clinical evidence-base in decision making; the meaning of DMT efficacy for PwRRMS; the influence of models of decision-making and information acquisition practices in PwRRMS; and the importance of psychosocial dimensions in DMT decision making. Synthesis of the findings revealed that alongside medical and individual reasoning, contextual circumstances play an important role in making treatment decisions.

Conclusion: This review identifies and explains the importance of diverse contextual circumstances (clinical, social, psychological) that are important for PwRRMS when making treatment decisions. The findings demonstrate the importance of eliciting, understanding and addressing such contextual factors.

Citing Articles

PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Evangelou N, Mattoscio M, Coutts M, Andiappan M, Sawtell T, Rhys K Int J MS Care. 2025; 27(Q1):1-7.

PMID: 39781371 PMC: 11704533. DOI: 10.7224/1537-2073.2023-079.


Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.

Sabin J, Salas E, Martin-Martinez J, Candeliere-Merlicco A, Barrero Hernandez F, Alonso Torres A Patient Prefer Adherence. 2024; 18:1163-1171.

PMID: 38863945 PMC: 11166147. DOI: 10.2147/PPA.S459242.


Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis.

Hoffmann O, Paul F, Haase R, Kern R, Ziemssen T Patient Prefer Adherence. 2024; 18:455-466.

PMID: 38406376 PMC: 10894675. DOI: 10.2147/PPA.S452849.


Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab.

Corallo F, Sessa E, Rifici C, De Cola M, Di Cara M, Cardile D J Clin Med. 2024; 13(1).

PMID: 38202019 PMC: 10779828. DOI: 10.3390/jcm13010013.


Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.

Sainz De La Maza S, Maurino J, Castillo-Trivino T, Borges M, Sebastian Torres B, Sotoca J Patient Prefer Adherence. 2023; 17:1431-1439.

PMID: 37337517 PMC: 10277026. DOI: 10.2147/PPA.S411069.